Shorter colorectal cancer screening intervals may be appropriate for patients with higher fecal hemoglobin concentrations on fecal immunochemical testing.
If colon cancer blood tests eventually win FDA approval and Medicare reimbursement, their use could become more widespread. But first this approach needs to match up against the current standard.